Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMPEL: Osimertinib plus Chemotherapy in EGFRm NSCLC
NCT04765059Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Sep 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Sep 2021; status: active, not recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04765059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04765059.